Palivizumab in preemies reduces wheezing, study finds

05/8/2013 | DoctorsLounge.com

Premature babies who were given monoclonal antibody palivizumab to protect against respiratory syncytial virus infection had 61% fewer days of wheezing in the first year of life than the placebo group, Dutch researchers found. They also noted a lower number of infants with recurrent wheeze in the palivizumab group. The study was published in the New England Journal of Medicine.

View Full Article in:

DoctorsLounge.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC